Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739879 | 1.00 | HDAC4 (0.46) | HDAC4HSD11B1AVPR1ALMNAMAPT | |
| SCHEMBL6742042 | 0.95 | HDAC4 (0.53) | HDAC4HSD11B1AVPR1ALMNAMAPT | |
| SCHEMBL6744990 | 0.95 | HDAC4 (0.50) | HDAC4HSD11B1AVPR1ALMNAMAPT | |
| SCHEMBL6744986 | 0.95 | HDAC4 (0.50) | HDAC4HSD11B1AVPR1ALMNAMAPT | |
| SCHEMBL6742036 | 0.95 | HDAC4 (0.53) | HDAC4HSD11B1AVPR1ALMNAMAPT | |
| SCHEMBL6744143 | 0.88 | HSD11B1 (0.43) | HDAC4HSD11B1LMNAMAPTHDAC1 | |
| SCHEMBL6744138 | 0.88 | HSD11B1 (0.43) | HDAC4HSD11B1LMNAMAPTHDAC1 | |
| SCHEMBL6736774 | 0.87 | HDAC4 (0.43) | HDAC4ALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL6736770 | 0.87 | HDAC4 (0.43) | HDAC4ALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL6744404 | 0.85 | MMP2 (0.46) | AVPR1AMAPTALDH1A1SMN1; SMN2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | DUAN JINGWU (US) | 2003-02-13 | — | — | US | claimed |
| US-6689771-B2 | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | DUAN JINGWU (US) | 2003-02-13 | — | — | US | disclosed |
| US-6376665-B1 | ANTIARTHRITIC AGENTS, ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | TNF, MMP1, ADAMTS1 | HDAC4 360/4885HSD11B1 1122/4885AVPR1A 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.